Quick answer: Semaglutide Research Peptide – 10 mg is presented by Nexigen as a research peptide for legitimate laboratory, analytical and scientific research. This page provides product-specific research context and links to related Nexigen research resources.
Semaglutide Research Material — Product Overview
Semaglutide is a synthetic modified peptide investigated extensively in laboratory research involving glucagon-like peptide-1 receptor biology, peptide-receptor interactions and metabolic signaling pathways.
Structurally, semaglutide is a modified GLP-1 analog containing 31 amino-acid residues together with structural modifications that distinguish it from endogenous GLP-1.
Nexigen Semaglutide 10 mg is supplied exclusively as a laboratory research material for analytical and scientific investigation.
The information presented on this page is intended to identify the compound, summarize relevant molecular and scientific research context, and provide researchers with reference information concerning semaglutide as a defined chemical entity.
FOR LABORATORY RESEARCH ONLY. NOT FOR HUMAN OR VETERINARY USE OR CONSUMPTION.
Semaglutide 10 mg — Research Specifications
| Specification | Information |
|---|---|
| Compound | Semaglutide |
| Quantity | 10 mg |
| Compound Type | Synthetic modified peptide / lipopeptide |
| Research Classification | GLP-1 receptor agonist research compound |
| Residue Count | 31 amino-acid residues |
| CAS Number | 910463-68-2 |
| PubChem CID | 56843331 |
| Molecular Formula | C187H291N45O59 |
| Molecular Weight | Approximately 4114 g/mol |
| Material Form | Research material; chemical form should be verified from applicable product documentation |
| Brand | Nexigen Peptides |
| Intended Use | Laboratory, analytical and scientific research only |
What Is Semaglutide?
Semaglutide is a synthetic modified peptide structurally related to glucagon-like peptide-1, commonly abbreviated GLP-1.
It has become an extensively studied molecular entity in research involving GLP-1 receptor signaling, peptide-receptor interactions, metabolic signaling and the structural behavior of modified peptide compounds.
Semaglutide contains 31 amino-acid residues and incorporates structural modifications that distinguish the molecule from naturally occurring GLP-1.
These modifications are important to researchers examining receptor interactions, molecular stability, peptide modification strategies and structure-function relationships.
Semaglutide and GLP-1 Receptor Research
The GLP-1 receptor is a member of the class B family of G-protein-coupled receptors and is widely studied in cellular signaling research.
Semaglutide has been used extensively as a reference compound in experimental systems investigating GLP-1 receptor activation and downstream signaling pathways.
Receptor Interaction
Research involving semaglutide includes investigation of ligand-receptor binding, receptor conformation, signaling kinetics and structure-function relationships associated with the GLP-1 receptor.
Cellular Signaling
GLP-1 receptor research frequently examines intracellular signaling systems activated following receptor interaction, including cyclic-AMP-associated pathways and other downstream molecular responses.
Structure-Function Research
Semaglutide provides researchers with a well-characterized example of how sequence modification and lipid-associated structural features can influence the properties of a peptide-receptor ligand.
Semaglutide Molecular Structure and Characteristics
Semaglutide is more structurally complex than an unmodified short peptide. In addition to its amino-acid sequence, the molecule incorporates chemical modifications and a lipid-associated side chain.
These features are relevant when evaluating molecular identity using chromatographic, mass-spectrometric and other analytical techniques.
For parent semaglutide, recognized reference characteristics include CAS number 910463-68-2, PubChem CID 56843331, molecular formula C187H291N45O59 and molecular weight of approximately 4114 g/mol.
Semaglutide Material Form and Chemical Identity
Researchers should distinguish parent semaglutide from salt- or counterion-associated semaglutide materials.
Material-form consideration: Semaglutide sodium, semaglutide acetate and other associated forms should not automatically be treated as chemically interchangeable with parent semaglutide. Molecular formula, molecular mass and analytical interpretation should correspond to the material actually being evaluated.
Nexigen should not assign a specific salt or counterion designation unless that designation is supported by verified information for the material being supplied.
Current Scientific and Regulatory Context
Semaglutide is also the active pharmaceutical ingredient in FDA-approved prescription drug products.
That pharmaceutical regulatory status is separate from the laboratory research material described on this page.
Nexigen Semaglutide 10 mg is not represented as Ozempic, Wegovy, Rybelsus or any other FDA-approved pharmaceutical product.
Nexigen does not represent this research material as a medicine, compounded drug, therapeutic product or substitute for an FDA-approved prescription product.
Nexigen does not provide human or veterinary dosing, administration, injection, reconstitution or treatment instructions.
Semaglutide Research Context
Scientific research involving semaglutide spans molecular biology, receptor pharmacology, structural biology, analytical chemistry and peptide engineering.
GLP-1 Receptor Biology
Semaglutide is frequently used in experimental research investigating GLP-1 receptor interaction and receptor-mediated cellular signaling.
Peptide Engineering
The molecule is also relevant to research examining how amino-acid substitutions and chemical modification can influence the physicochemical properties of peptide-based research compounds.
Structural Biology
Structural studies involving the GLP-1 receptor and peptide ligands contribute to understanding receptor-ligand interactions at the molecular level.
Analytical Chemistry
Because semaglutide is a comparatively large and chemically modified peptide, analytical characterization may require complementary techniques capable of evaluating chromatographic behavior, molecular identity and structural characteristics.
Experimental Research Characteristics
Researchers working with semaglutide should consider several characteristics when designing analytical or experimental workflows.
- Modified peptide structure
- 31-residue amino-acid framework
- Lipid-associated structural modification
- GLP-1 receptor interaction
- Material form
- Analytical methodology
- Sample preparation
- Experimental concentration
- Assay conditions
Experimental findings should always be interpreted in relation to the specific model, methodology and material characteristics used in the investigation.
Evaluating Semaglutide as a Research Material
Compound Identity
The product name, CAS number, molecular formula, molecular mass and structural information should correspond to the same chemical entity.
Material Form
Researchers should determine whether a material represents parent semaglutide or another specifically identified chemical form before interpreting molecular-mass or analytical data.
Analytical Methodology
Different analytical techniques provide different types of information. Chromatographic separation alone does not provide the same information as molecular-mass or structural analysis.
Research Documentation
Researchers should retain applicable material-identification and analytical records as part of normal laboratory quality-control procedures.
Analytical Evaluation of Semaglutide
HPLC
High-performance liquid chromatography can be used to examine the chromatographic profile of semaglutide research material under defined analytical conditions.
Chromatographic behavior depends upon factors including column chemistry, mobile phase, gradient conditions, detector configuration and sample preparation.
LC-MS
Liquid chromatography-mass spectrometry combines chromatographic separation with molecular-mass-related information and can provide complementary evidence when evaluating semaglutide identity.
Mass Spectrometry
Mass spectrometry can provide information concerning molecular ions, charge states, isotopic distributions and related species associated with peptide characterization.
Orthogonal Analysis
Combining complementary analytical techniques can provide a more complete characterization than relying upon a single chromatographic result.
Laboratory Handling
Semaglutide research material should be handled using standard laboratory procedures appropriate for synthetic peptide research compounds.
Experimental preparation requirements depend upon the analytical method, research design, solvent system and laboratory protocol.
Researchers should follow validated internal laboratory procedures and relevant scientific literature for the specific analytical workflow being performed.
Nexigen does not provide instructions for human or veterinary preparation, reconstitution, administration, injection or dosing.
Storage of Semaglutide Research Material
Research material should be stored according to the conditions specified on applicable product documentation and handled in a manner intended to minimize unnecessary exposure to moisture, light, heat or repeated environmental fluctuations.
Laboratories should follow validated compound-specific stability procedures where such information is available rather than assuming generalized storage conditions apply to every semaglutide material or chemical form.
Semaglutide Research Resources
What Is Semaglutide?
A scientific introduction to semaglutide, GLP-1 receptor research, molecular identity and laboratory research context.
Semaglutide Sequence, Structure and Molecular Characteristics
A closer examination of semaglutide’s modified peptide structure, molecular characteristics and research significance.
Semaglutide Research in 2026
An overview of current scientific literature involving GLP-1 receptor biology, structural research and emerging semaglutide research directions.
Semaglutide Analytical Testing
A research-focused guide to HPLC, LC-MS, mass spectrometry and complementary analytical techniques used in peptide characterization.
Selected Scientific Reference Information
PubChem — Semaglutide
PubChem identifies semaglutide as CID 56843331, CAS 910463-68-2, molecular formula C187H291N45O59 and molecular weight of approximately 4114 g/mol.
U.S. Food and Drug Administration
FDA materials document semaglutide as the active ingredient in approved prescription pharmaceutical products and separately address regulatory concerns involving unapproved and compounded semaglutide materials.
Semaglutide Research FAQ
What is semaglutide?
Semaglutide is a synthetic modified peptide structurally related to GLP-1 and widely studied in laboratory research involving GLP-1 receptor signaling, peptide structure and molecular characterization.
How many amino-acid residues does semaglutide contain?
Semaglutide contains 31 amino-acid residues together with additional structural modifications.
What is the CAS number for semaglutide?
The CAS number associated with parent semaglutide is 910463-68-2.
What is the PubChem CID for semaglutide?
The PubChem Compound ID for semaglutide is 56843331.
What is the molecular formula of semaglutide?
The molecular formula reported for parent semaglutide is C187H291N45O59.
What is the molecular weight of semaglutide?
PubChem reports a molecular weight of approximately 4114 g/mol for parent semaglutide.
Is semaglutide a GLP-1 research compound?
Yes. Semaglutide is widely investigated in scientific research involving GLP-1 receptor biology, receptor signaling and peptide structure-function relationships.
Are semaglutide and semaglutide sodium identical materials?
No. Parent semaglutide and semaglutide sodium are separately represented chemical forms and should not automatically be treated as analytically interchangeable.
Is Nexigen Semaglutide an FDA-approved pharmaceutical product?
No. Nexigen Semaglutide 10 mg is presented exclusively as laboratory research material and is not represented as any FDA-approved semaglutide pharmaceutical product.
Does Nexigen provide semaglutide dosing or reconstitution instructions?
No. Nexigen does not provide human or veterinary dosing, injection, administration or reconstitution instructions.
What is Nexigen Semaglutide intended for?
Nexigen Semaglutide 10 mg is intended exclusively for legitimate laboratory, analytical and scientific research.
Research Use Only
Nexigen Semaglutide 10 mg is supplied exclusively for legitimate laboratory, analytical and scientific research.
This material is not represented as Ozempic, Wegovy, Rybelsus or any other FDA-approved pharmaceutical product and is not intended for human or veterinary use or consumption, clinical use, diagnosis, treatment, cure or prevention of disease.
Nexigen Peptides does not provide medical advice, human or personal-use guidance.
